Navigation Sciences

Navigation Sciences (LSI USA ‘25 Innovator) is developing the NaviSci? System for the tissue-conserving removal of lung cancer and other soft tissue tumors. The system integrates Augmented Reality (AR) and advanced software with surgical hardware to guide precise surgical resection by enabling, for the first time, real-time in-vivo measurement of the surrounding tissue in relation to the surgical instrumentation. The NaviSci System has the potential to transform lung cancer surgery in the way that early-stage breast cancer surgery evolved from mastectomy to lumpectomy. With increasing detection of early-stage tumors at a point where surgical treatment may be curative and the emergence of minimally invasive surgery as the standard of care for early-stage lung cancer, the System’s capability has enormous potential to ensure resection with appropriate margins and thereby reduce recurrence risk, conserve lung function, shorten hospital stay and enhance surgical workflow. Recently, the NaviSci System was selected as a candidate by The Galien Foundation for its annual ‘Best Start Up’ award. The Prix Galien prizes, awarded since 1970, are considered the Nobel Prize in healthcare and life sciences research and development. They recognize outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The company has completed a 25-patient clinical feasibility trial at Brigham and Women's Hospital in Boston. It confirmed the System’s utility in providing real-time margin assessment, demonstrated it was safe and effective, and correlated the margin measurements with pathology lab findings. The company plans to complete the System’s development in preparation for an FDA submission in 2025. We’re excited to announce that Alan Lucas has been selected to present Navigation Sciences at LSI USA ‘25 March 17-21, 2025. Join us in Dana Point to meet with Alan and learn more about Navigation Sciences.

Yesterday Jayender Jagadeesan shared a presentation on imaging, robotics and machine learning for surgery at Bengaluru Tech Summit featuring the NaviSci? System's technology for minimally invasive precision surgery. Stop by our shared booth with POSSPOLE to learn more about the NaviSci System! #BengaluruTechSummit2024 #NaviSci #PrecisionSurgery

The European Patent Office granted a key patent on November 6th covering Navigation Sciences’ NaviSci? System for the minimally invasive precision localization and resection of lung and other cancers with real-time surgical margin control. The patent, “System for a tissue resection margin measurement device,” is the company’s first issued under the International Patent Cooperation Treaty (PCT) and is being validated in the U.K., France, Germany, and Switzerland (including Lichtenstein). The newly awarded patent broadly covers the system for resecting lung tumors while compensating for tissue deformation. The company has additional international and U.S. patents pending. The patents cover technology licensed from MassGeneral Brigham hospitals. Learn more by reading the attached press release. #EuropeanPatent #MassGeneralBrigham #PrecisionSurgicalResection

Congratulations to the winners of The Galien Foundation awards! The Navigation Sciences team was honored to be included among the nominees in the "Best Startup" award category. The NaviSci System? is designed to fill a large and growing need to provide real-time intraoperative measurements during surgery to ensure appropriate margins with a surgical resection. #GalienAwards #GalienFoundation2024 #MedicalTechnology

Curious about the NaviSci System ahead of The Galien Foundation awards ceremony? Here's an overview of how the system works and why this is an imperative invention for precision surgery for lung and soft tissue cancers. #GalienPrixAwards #NaviSciSystem #HowItWorks

Our CEO Alan Lucas and company advisory board member Kurt Kruger will be attending the The Galien Foundation awards gala this Thursday in New York City. The awards, which are considered the Nobel Prize in healthcare and life sciences research and development, recognize “outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments.” Navigation Sciences’ NaviSci? System for the precision localization and resection of lung tumors is an award nominee in the ‘Best Startup” category. The NaviSci System is designed to fill a large and growing need to provide real-time intraoperative measurements during surgery to ensure appropriate margins with a surgical resection. #PrixGalienUSA #GalienAwards #NaviSciSystem ?

We are pleased to announce that Navigation Sciences has been selected to present an update on the company’s progress at LSI 2025 on March 17-21 in Monarch Beach, CA. Navigation Sciences is developing the NaviSci? System for the tissue conserving removal of lung cancer and other soft tissue tumors. The system integrates Augmented Reality (AR) and advanced software with surgical hardware to guide precise surgical resection by enabling, for the first time, real-time in-vivo measurement of the surrounding tissue in relation to the surgical instrumentation. The NaviSci System has potential to transform lung cancer surgery in the way that early-stage breast cancer surgery evolved from mastectomy to lumpectomy. With increasing detection of early-stage tumors at a point where surgical treatment may be curative and the emergence of minimally invasive surgery as the standard of care for early-stage lung cancer, the System’s capability has enormous potential to ensure resection with appropriate margins and thereby reduce recurrence risk, conserve lung function, shorten hospital stay and enhance surgical workflow. Recently, the NaviSci System was selected as a candidate by The Galien Foundation for its annual ‘Best Start Up’ award. The Prix Galien prizes, awarded since 1970, are considered the Nobel Prize in healthcare and life sciences research and development. They recognize outstanding achievements in improving the global human condition through the development of innovative drugs and other treatments. The company has completed a 25-patient clinical feasibility trial at Brigham and Women's Hospital in Boston. It confirmed the System’s utility in providing real-time margin assessment, demonstrated it was safe and effective, and correlated the margin measurements with pathology lab findings. The company plans to complete the System’s development in preparation for an FDA submission in 2025.

We'll be attending The MedTech Conference in Toronto next week from October 15-17, 2024! This event brings together over 3,500 attendees and features more than 100 sessions covering everything from digital health to AI in healthcare. Plus, with 400+ speakers and cutting-edge exhibitors, it’s the place to be if you want to stay ahead in the medtech world. Don’t miss this chance to network, learn, and discover the latest innovations shaping the future of healthcare. We hope to see you there! #MedTechCon #MTC24

Navigation Sciences will be at RESI Boston #RESIBOSTON tomorrow, September 25th. Send us a meeting request: https://lnkd.in/gEecZet5? View the program guide: https://lnkd.in/e7iNwSFW

Curious about how the NaviSci System? works? In this brief overview,?CEO?Alan Lucas breaks down how the NaviSci System measures?and displays?the distance between the?resection device and the tumor?to guide the surgeon?and?ensure tissue is removed at a safe margin. This advanced technology empowers surgeons with precision, helping to ensure better outcomes for patients. Watch the video to learn more about this innovative system and how it can transform?lung?and surgical oncology procedures. #SurgicalInnovation #MedicalTechnology #PrecisionSurgery #PatientCare #MedicalDevices #LSI